KRYS
Krystal Biotech, Inc.
NasdaqGSUSDEQUITY
Healthcare
DELAYED
Neutral
+18/100
Last price
326.81
▼ 8.04 (2.40%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
334.50
Prev close
334.85
Day high
335.16
Day low
319.61
Volume
352.02K
Market cap
$9.67B
P/E (TTM)
41.95
52W range
179.19 – 382.54
Day trading desk
Gap from prior close
-0.10%
Prior close 334.85
VWAP
326.99
-0.05% from price
Relative volume
1.70×
Unusually busy
Session range
6.07%
319.61 – 339.00
Position in range
37%
Mid range
ATR (14D)
10.96
3.35% of price
Prior day high
339.69
PDH
Prior day low
321.36
PDL
Bid / ask spread
—
Quote not published
Session volume
645.07K
Avg 379.32K
VWAP and the session figures are computed from the delayed intraday series on this page, so they lag the live tape and will not match a broker's real-time VWAP exactly. Turn on Prior day H/L/C, Opening range and Volume profile in the chart's Studies menu to see these levels drawn on price.
Trailing performance
Returnvs SPY
1W
-2.46%
-4.4%
1M
-8.77%
-9.9%
3M
-12.94%
-17.5%
6M
+23.80%
+5.6%
YTD
+32.56%
+18.3%
1Y
+78.23%
+61.8%
3Y
+181.73%
+99.5%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on KRYS open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
-121.95K
Net selling
Buy transactions
2
4.69K shares
Sell transactions
7
126.64K shares
Net transactions
+9
Buys less sells
Sell : buy shares
27.0 : 1
Heavily one-sided
Insider-held shares
3.15M
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Sep 4, 26 | KRISHNAN SUMA M Officer, Director and Beneficial Owner |
SELL | 25.00K | $8.98M | Direct |
| Sep 4, 26 | KRISHNAN KRISH S Chief Executive Officer |
SELL | 25.00K | $8.98M | Direct |
| Aug 14, 26 | ROSSI DINO A Director |
STOCK | 3.69K | $0 | Direct |
| Aug 14, 26 | ROSSI DINO A Director |
SELL | 25.00K | $8.23M | Direct |
| Jun 25, 26 | THOMAS JOHN CHARLES MICHAEL General Counsel |
CONVERSION | 1.00K | $179.25K | Direct |
| Jun 25, 26 | THOMAS JOHN CHARLES MICHAEL General Counsel |
SELL | 1.00K | $347.27K | Direct |
| Jun 4, 26 | KRISHNAN SUMA M Officer, Director and Beneficial Owner |
SELL | 25.00K | $7.70M | Direct |
| Jun 4, 26 | KRISHNAN KRISH S Chief Executive Officer |
SELL | 25.00K | $7.70M | Direct |
| May 26, 26 | THOMAS JOHN CHARLES MICHAEL General Counsel |
SELL | 642 | $193.90K | Direct |
| Mar 4, 26 | KRISHNAN SUMA M Officer, Director and Beneficial Owner |
SELL | 25.00K | $6.58M | Direct |
| Mar 4, 26 | KRISHNAN KRISH S Chief Executive Officer |
SELL | 25.00K | $6.58M | Direct |
| Mar 2, 26 | ROMANO KATHRYN Officer |
SELL | 750 | $200.70K | Direct |
| Feb 27, 26 | KRISHNAN SUMA M Officer, Director and Beneficial Owner |
— | 67.22K | — | |
| Feb 27, 26 | KRISHNAN KRISH S Chief Executive Officer |
— | 67.22K | — |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
JANNEY DANIEL SPENCER |
Director | — | Sale |
KRISHNAN KRISH S |
Chief Executive Officer | 1.57M | Sale |
KRISHNAN SUMA M |
Officer, Director and Beneficial Owner | 1.49M | Sale |
ROMANO KATHRYN |
Officer | 22.37K | Sale |
ROSSI DINO A |
Director | 50.00K | Stock Gift |
THOMAS JOHN CHARLES MICHAEL |
General Counsel | 0 | Conversion of Exercise of derivative security |
Fundamentals
Market cap$9.67B
Enterprise value$8.84B
Revenue (TTM)$440.48M
Gross profit$416.87M
EBITDA$199.29M
Net income$241.46M
EPS (TTM)$7.79
Free cash flow$151.74M
Total cash$845.63M
Total debt$8.85M
Book value / share$45.92
Shares outstanding29.60M
Float23.62M
Short % of float17.50%
Dividend yield0.00%
Beta (5Y)0.50
Valuation & profitability ratios
Trailing P/E41.95
Forward P/E35.07
PEG ratio—
Price / sales—
Price / book7.12
EV / revenue20.06
EV / EBITDA44.34
Gross margin94.64%
Operating margin49.00%
Profit margin54.82%
Return on equity20.12%
Return on assets9.37%
Debt / equity0.65
Current ratio8.32
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $389.13M | $290.51M | $50.70M | $0 | +33.9% |
| Operating revenue | $389.13M | $290.51M | $50.70M | $0 | +33.9% |
| Cost of revenue | $23.05M | $20.06M | $3.09M | $0 | +14.9% |
| Gross profit | $366.08M | $270.45M | $47.60M | $0 | +35.4% |
| Research & development | $58.05M | $53.58M | $46.43M | $42.46M | +8.3% |
| Selling, general & admin | $146.74M | $113.63M | $98.29M | $77.73M | +29.1% |
| Total operating expense | $204.79M | $167.21M | $144.72M | $120.20M | +22.5% |
| Operating income | $161.29M | $103.25M | -$97.12M | -$120.20M | +56.2% |
| Net interest income | $28.18M | $29.61M | $22.51M | $5.22M | -4.8% |
| Pre-tax income | $189.47M | $95.36M | $12.90M | -$139.97M | +98.7% |
| Tax provision | -$15.36M | $6.20M | $1.97M | $0 | -347.9% |
| Net income | $204.83M | $89.16M | $10.93M | -$139.97M | +129.7% |
| Net income to common | $204.83M | $89.16M | $10.93M | -$139.97M | +129.7% |
| Basic EPS | 7.08 | 3.12 | 0.40 | -5.49 | +126.9% |
| Diluted EPS | 6.84 | 3.00 | 0.39 | -5.49 | +128.0% |
| EBIT | $161.29M | $103.25M | -$97.12M | -$120.20M | +56.2% |
| EBITDA | $167.85M | $109.96M | -$91.21M | -$116.81M | +52.6% |
| Basic shares | 28.94M | 28.59M | 27.15M | 25.49M | +1.2% |
| Diluted shares | 29.95M | 29.74M | 27.75M | 25.49M | +0.7% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Cash & equivalents | $496.30M | $344.87M | $358.33M | $161.90M | +43.9% |
| Cash & short-term investments | $827.79M | $597.52M | $532.18M | $379.17M | +38.5% |
| Accounts receivable | $127.42M | $104.75M | $42.04M | $0 | +21.7% |
| Inventory | $40.48M | $26.51M | $6.99M | $0 | +52.7% |
| Total current assets | $1.02B | $742.04M | $587.91M | $383.78M | +38.1% |
| Property, plant & equipment | $158.01M | $161.45M | $168.23M | $169.73M | -2.1% |
| Total assets | $1.33B | $1.06B | $818.36M | $558.45M | +26.3% |
| Total current liabilities | $102.94M | $102.00M | $33.09M | $28.85M | +0.9% |
| Total debt | $9.34M | $7.26M | $8.09M | $8.93M | +28.6% |
| Total liabilities | $114.23M | $109.46M | $39.71M | $36.22M | +4.4% |
| Retained earnings | $24.16M | -$180.67M | -$269.83M | -$280.76M | +113.4% |
| Shareholder equity | $1.22B | $946.38M | $778.64M | $522.23M | +28.9% |
| Working capital | $921.66M | $640.05M | $554.82M | $354.93M | +44.0% |
| Net tangible assets | $1.22B | $946.38M | $778.64M | $522.23M | +28.9% |
| Shares issued | 29.19M | 28.79M | 28.24M | 25.76M | +1.4% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Net income | $204.83M | $89.16M | $10.93M | -$139.97M | +129.7% |
| Depreciation & amortisation | $6.55M | $6.71M | $5.91M | $3.38M | -2.4% |
| Stock-based compensation | $54.51M | $49.13M | $39.93M | $33.23M | +11.0% |
| Change in working capital | -$36.42M | -$14.46M | -$38.52M | $2.66M | -151.9% |
| Operating cash flow | $200.87M | $123.42M | -$88.80M | -$100.57M | +62.7% |
| Capital expenditure | -$11.95M | -$4.24M | -$11.80M | -$52.98M | -182.0% |
| Investing cash flow | -$58.42M | -$163.44M | $82.64M | -$114.08M | +64.3% |
| Financing cash flow | $8.71M | $27.01M | $202.75M | $35.35M | -67.8% |
| Free cash flow | $188.91M | $119.18M | -$100.60M | -$153.55M | +58.5% |
| End cash position | $496.30M | $344.87M | $358.33M | $161.90M | +43.9% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Total revenue | $119.22M | $116.36M | $107.11M | $97.80M | $96.04M | +2.5% |
| Operating revenue | $119.22M | $116.36M | $107.11M | $97.80M | $96.04M | +2.5% |
| Cost of revenue | $6.44M | $6.32M | $6.59M | $4.26M | $7.17M | +1.8% |
| Gross profit | $112.78M | $110.03M | $100.51M | $93.54M | $88.88M | +2.5% |
| Research & development | $14.52M | $15.33M | $14.79M | $14.59M | $14.41M | -5.3% |
| Selling, general & admin | $39.85M | $41.01M | $41.45M | $37.58M | $35.07M | -2.8% |
| Total operating expense | $54.37M | $56.34M | $56.24M | $52.16M | $49.48M | -3.5% |
| Operating income | $58.42M | $53.69M | $44.27M | $41.37M | $39.40M | +8.8% |
| Net interest income | $7.66M | $7.75M | $6.86M | $6.59M | $7.38M | -1.2% |
| Pre-tax income | $66.08M | $61.44M | $51.13M | $47.97M | $46.77M | +7.5% |
| Tax provision | $11.31M | $5.51M | -$269.00K | -$31.40M | $8.44M | +105.3% |
| Net income | $54.77M | $55.93M | $51.40M | $79.36M | $38.33M | -2.1% |
| Net income to common | $54.77M | $55.93M | $51.40M | $79.36M | $38.33M | -2.1% |
| Basic EPS | 1.85 | 1.91 | 1.77 | 2.74 | 1.33 | -3.1% |
| Diluted EPS | 1.79 | 1.83 | 1.70 | 2.66 | 1.29 | -2.2% |
| EBIT | $58.42M | $53.69M | $44.27M | $41.37M | $39.40M | +8.8% |
| EBITDA | $59.98M | $55.41M | $46.03M | $42.99M | $40.94M | +8.2% |
| Basic shares | 29.53M | 29.29M | 29.09M | 28.95M | 28.91M | +0.8% |
| Diluted shares | 30.66M | 30.51M | 30.25M | 29.83M | 29.75M | +0.5% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $427.74M | $501.31M | $496.30M | $392.60M | $353.83M | -14.7% |
| Cash & short-term investments | $845.63M | $823.40M | $827.79M | $731.07M | $681.99M | +2.7% |
| Accounts receivable | $138.66M | $127.02M | $127.42M | $129.63M | $111.44M | +9.2% |
| Inventory | $45.56M | $42.65M | $40.48M | $37.63M | $31.04M | +6.8% |
| Total current assets | $1.06B | $1.02B | $1.02B | $925.65M | $841.35M | +3.9% |
| Property, plant & equipment | $160.60M | $160.62M | $158.01M | $156.32M | $158.04M | -0.0% |
| Total assets | $1.50B | $1.40B | $1.33B | $1.24B | $1.14B | +7.4% |
| Total current liabilities | $127.40M | $107.80M | $102.94M | $91.27M | $86.90M | +18.2% |
| Total debt | $8.85M | $9.11M | $9.34M | $9.51M | $9.68M | -2.8% |
| Total liabilities | $141.52M | $120.24M | $114.23M | $102.22M | $97.75M | +17.7% |
| Retained earnings | $134.86M | $80.09M | $24.16M | -$27.24M | -$106.60M | +68.4% |
| Shareholder equity | $1.36B | $1.28B | $1.22B | $1.14B | $1.04B | +6.5% |
| Working capital | $932.25M | $911.94M | $921.66M | $834.38M | $754.45M | +2.2% |
| Net tangible assets | $1.36B | $1.28B | $1.22B | $1.14B | $1.04B | +6.5% |
| Shares issued | 29.60M | 29.44M | 29.19M | 28.98M | 28.93M | +0.5% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Net income | $54.77M | $55.93M | $51.40M | $79.36M | $38.33M | -2.1% |
| Depreciation & amortisation | $1.57M | $1.73M | $1.76M | $1.61M | $1.54M | -9.3% |
| Stock-based compensation | $14.16M | $13.61M | $13.76M | $13.15M | $14.12M | +4.0% |
| Change in working capital | $5.62M | $10.08M | $9.50M | -$27.88M | $494.00K | -44.3% |
| Operating cash flow | $74.79M | $80.38M | $77.51M | $39.66M | $52.73M | -7.0% |
| Capital expenditure | -$3.56M | -$7.15M | -$2.14M | -$1.70M | -$1.90M | +50.1% |
| Investing cash flow | -$161.58M | -$63.58M | $11.16M | -$4.29M | -$10.53M | -154.1% |
| Financing cash flow | $15.05M | -$10.46M | $15.67M | $3.71M | $1.80M | +243.9% |
| Free cash flow | $71.22M | $73.23M | $75.37M | $37.95M | $50.83M | -2.7% |
| End cash position | $427.74M | $501.31M | $496.30M | $392.60M | $353.83M | -14.7% |
Options analytics
Put / call volume
0.21
Call-heavy session
Put / call open interest
0.40
Positioning, not flow
Max pain
340.00
+4.0% from spot
ATM implied vol
49.4%
Nearest strike to spot
Skew (10% OTM)
+8.4%
Puts bid over calls
Call volume
164
Contracts, this expiry
Put volume
35
Contracts, this expiry
Heaviest call OI
350.00
528 contracts
Heaviest put OI
320.00
207 contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | 1.91 | 1.79 | -6.5% |
| Mar 2026 | 1.42 | 1.83 | +29.0% |
| Dec 2025 | 1.61 | 1.70 | +5.8% |
| Sep 2025 | 1.12 | 2.66 | +137.0% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | 2.00 | 10 | $129.86M | +32.8% |
| Next quarter | 2.24 | 10 | $143.93M | +34.4% |
| Current year | 7.87 | 11 | $511.06M | +31.3% |
| Next year | 9.32 | 11 | $651.87M | +27.6% |
Analyst targets & ownership
Mean target$392.11
High target$474.00
Low target$284.00
Implied upside19.98%
Analyst count9
ConsensusSTRONG BUY
Strong buy / Buy1 / 10
Hold1
Sell / Strong sell0 / 0
Held by insiders10.66%
Held by institutions102.43%
Institutions holding574
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
334.65
-2.34% from price
SMA 20
338.03
-3.32% from price
SMA 50
341.92
-4.42% from price
SMA 100
337.36
-3.13% from price
SMA 200
302.31
+8.10% from price
EMA 12
334.14
-2.19% from price
EMA 26
338.80
-3.54% from price
EMA 50
339.69
-3.79% from price
RSI (14)
42.0
Neutral
MACD (12,26,9)
-4.66
Hist -1.55
ATR (14)
10.96
3.35% of price
Realised vol 30D
31.9%
Annualised
Bollinger upper
353.12
20, 2σ
Bollinger lower
322.94
20, 2σ
50 / 200 cross
Golden
341.92 vs 302.31
Trend bias
Above 200
+8.10%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
0.76
Less volatile than market
Correlation to SPY
0.26
Largely independent
Realised vol 30D
31.9%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-17.3%
Peak to trough
Max drawdown 5Y
-44.5%
Peak to trough
ATR 14
10.96
3.35% of price
Beta (reported)
0.50
5Y monthly, from filing
Short interest
Shares short
3.16M
Prior 3.20M
Change vs prior
-1.3%
Shorts covering
% of float
17.50%
Elevated
% of shares out
10.69%
Against total outstanding
Days to cover
13.7
Crowded exit
Float
23.62M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Sep 21, 26 | B of A Securities | MAINTAINED | Buy | Buy |
| Aug 14, 26 | RBC Capital | INITIATED | — | Outperform |
| Aug 4, 26 | Citigroup | MAINTAINED | Buy | Buy |
| Jul 14, 26 | B of A Securities | MAINTAINED | Buy | Buy |
| Jun 18, 26 | TD Cowen | MAINTAINED | Buy | Buy |
| Jun 16, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Jun 1, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| May 22, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| May 18, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| May 5, 26 | Citigroup | MAINTAINED | Buy | Buy |
| May 5, 26 | Evercore ISI Group | MAINTAINED | Outperform | Outperform |
| May 4, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
Dividends & splits
Forward rate—
Forward yield0.00%
5-year avg yield—
Payout ratio0.00%
Ex-dividend date—
Next pay date—
Last split—
Split date—
SEC filings
Corporate Changes & Voting Matters
8-K · 2026-08-03
Corporate Changes & Voting Matters
8-K · 2026-07-21
Corporate Changes & Voting Matters
8-K · 2026-05-20
Periodic Financial Reports
10-Q · 2026-05-04
Proxy Statements
DEF 14A · 2026-04-03
Corporate Changes & Voting Matters
8-K · 2026-02-17
Corporate Changes & Voting Matters
8-K · 2026-01-12
Corporate Changes & Voting Matters
8-K · 2026-01-08
Headlines
Krystal Biotech (KRYS) Has a Blockbuster Rare-Disease Drug. Is Its Moat Durable?
Insider Monkey · 24h ago
BofA Adjusts Price Target on Krystal Biotech to $400 From $392, Keeps Buy Rating
MT Newswires · 16d ago
Krystal Biotech Insider Sold Shares Worth $8,983,084, According to a Recent SEC Filing
MT Newswires · 29d ago
Krystal Biotech Insider Sold Shares Worth $8,982,986, According to a Recent SEC Filing
MT Newswires · 29d ago
Krystal Stock Gains 13.4% in a Month: What Is Driving the Rally?
Zacks · 33d ago
Why Is Amgen (AMGN) Up 8.6% Since Last Earnings Report?
Zacks · 33d ago
Krystal Biotech to Present at 2026 Cantor Global Healthcare Conference
GlobeNewswire · 34d ago
Krystal Biotech (KRYS) Up 12% Since Last Earnings Report: Can It Continue?
Zacks · 34d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.